ArticleJCO precision oncology2026
Novel Genomic Biomarkers Improve Post-Hematopoietic Cell Transplantation Relapse Risk Stratification for Patients With Myelodysplastic Syndromes.
Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeHematopoietic cell transplantation (HCT) is considered the only curative treatment for patients with myelodysplastic syndrome (MDS), with disease relapse (REL) as the major cause of post-HCT failure. We aimed to conduct a comprehensive genomic screening of prognostic biomarkers associated with post-HCT disease relapse.
methodsIn this retrospective, cohort study, we analyzed whole-genome sequencing data from 494 non-Hispanic White patients with MDS who received HCT in the Center for International Blood and Marrow Transplant Research network. Genomic prognostic biomarkers were determined by cause-specific Cox regression multivariable models, with additional sensitivity analyses on unrelated transplant subcohorts and different competing outcomes. Their clinical significance on post-HCT risk stratifications was further evaluated via random survival forest models with optimism-bias adjusted bootstrap procedure.
resultsTen novel genomic biomarkers associated with relapse were identified, including somatic mutations in two genes (
conclusionOur results suggest that SNVs and SVs beyond recurrent somatic mutations and cytogenetic abnormalities may play important roles in determining post-HCT relapse risk stratification in patients with MDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.